Last reviewed · How we verify
Dexchlorpheniramine, pseudoephedrine, guaifenesin
Dexchlorpheniramine, pseudoephedrine, guaifenesin is a Antihistamine/decongestant/expectorant combination Small molecule drug developed by Mantecorp Industria Quimica e Farmaceutica Ltd.. It is currently in Phase 3 development for Allergic rhinitis with nasal congestion and cough, Common cold with allergic symptoms and congestion.
This combination drug reduces allergy symptoms via antihistamine action, nasal congestion via sympathomimetic decongestant, and cough via expectorant action.
This combination drug reduces allergy symptoms via antihistamine action, nasal congestion via sympathomimetic decongestant, and cough via expectorant action. Used for Allergic rhinitis with nasal congestion and cough, Common cold with allergic symptoms and congestion.
At a glance
| Generic name | Dexchlorpheniramine, pseudoephedrine, guaifenesin |
|---|---|
| Sponsor | Mantecorp Industria Quimica e Farmaceutica Ltd. |
| Drug class | Antihistamine/decongestant/expectorant combination |
| Target | H1 receptor (dexchlorpheniramine); alpha-1 adrenergic receptor (pseudoephedrine) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Allergy |
| Phase | Phase 3 |
Mechanism of action
Dexchlorpheniramine is a first-generation H1-receptor antagonist that blocks histamine-mediated allergic responses. Pseudoephedrine is an alpha-adrenergic agonist that causes vasoconstriction in nasal blood vessels to reduce congestion. Guaifenesin is an expectorant that thins respiratory secretions to facilitate clearance of mucus.
Approved indications
- Allergic rhinitis with nasal congestion and cough
- Common cold with allergic symptoms and congestion
Common side effects
- Drowsiness
- Dry mouth
- Nervousness or insomnia
- Tachycardia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexchlorpheniramine, pseudoephedrine, guaifenesin CI brief — competitive landscape report
- Dexchlorpheniramine, pseudoephedrine, guaifenesin updates RSS · CI watch RSS
- Mantecorp Industria Quimica e Farmaceutica Ltd. portfolio CI
Frequently asked questions about Dexchlorpheniramine, pseudoephedrine, guaifenesin
What is Dexchlorpheniramine, pseudoephedrine, guaifenesin?
How does Dexchlorpheniramine, pseudoephedrine, guaifenesin work?
What is Dexchlorpheniramine, pseudoephedrine, guaifenesin used for?
Who makes Dexchlorpheniramine, pseudoephedrine, guaifenesin?
What drug class is Dexchlorpheniramine, pseudoephedrine, guaifenesin in?
What development phase is Dexchlorpheniramine, pseudoephedrine, guaifenesin in?
What are the side effects of Dexchlorpheniramine, pseudoephedrine, guaifenesin?
What does Dexchlorpheniramine, pseudoephedrine, guaifenesin target?
Related
- Drug class: All Antihistamine/decongestant/expectorant combination drugs
- Target: All drugs targeting H1 receptor (dexchlorpheniramine); alpha-1 adrenergic receptor (pseudoephedrine)
- Manufacturer: Mantecorp Industria Quimica e Farmaceutica Ltd. — full pipeline
- Therapeutic area: All drugs in Respiratory/Allergy
- Indication: Drugs for Allergic rhinitis with nasal congestion and cough
- Indication: Drugs for Common cold with allergic symptoms and congestion
- Compare: Dexchlorpheniramine, pseudoephedrine, guaifenesin vs similar drugs
- Pricing: Dexchlorpheniramine, pseudoephedrine, guaifenesin cost, discount & access